Privigen Approval History
- FDA approved: Yes (First approved July 26th, 2007)
- Brand name: Privigen
- Generic name: immune globulin intravenous (human)
- Company: CSL Behring
- Treatment for: Primary Immunodeficiency Syndrome, Idiopathic Thrombocytopenic Purpura
Privigen is an immune globulin intravenous (human), 10% liquid indicated for treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura.
FDA Approval History for Privigen
|Apr 19, 2010||CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen from 24 to 36 Months|
|Jul 27, 2007||CSL Behring Announces FDA Approval of Privigen-- First Proline-Stabilized 10 Percent Liquid IVIg|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.